New clinical data from UniQure's AMT-130 gene therapy reveal a substantial slowing of Huntington's disease progression by 75% over three years in treated patients, meeting the primary composite Unified Huntington’s Disease Rating Scale endpoint and key secondary measures. These results, presented by leading neurologists and backed by robust statistical analysis, affirm the therapy's potential as the first disease-modifying treatment for Huntington’s with a single-dose, intracranial administration. UniQure plans FDA submission in Q1 2026, marking a historic milestone in neurodegenerative disease treatment.